Yuken India Q2 FY26 results: revenue dips, profits decline

Revenue declinedEBITDA margin compressionResults View source PDF Explain this filing

YUKEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹911.00

prior close

₹929.15

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-0.5% vs market

Compressors Pumps & Diesel Engines peers, median of 12sector-0.4%-0.1% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.1 pts less than its Compressors Pumps & Diesel Engines peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-2.6

15m

-3.0

30m

-4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6-0.1-0.5-0.4-0.1

Next day

-1.9-0.2-1.7-1.0-0.9

-0.3+0.4-0.7+0.3-0.6

+1.5-0.4+1.9-1.4+2.9

-1.3-0.6-0.7-2.6+1.3

-1.8-0.9-0.9-1.8+0.0

-4.5-3.0-1.5-5.3+0.8

15d

-6.4-3.9-2.5-4.5-1.9

-6.6-4.8-1.8-2.7-3.9

-11.6-7.8-3.9-9.0-2.6

-15.8-7.2-8.6-8.0-7.8

UpDownMarket · Nifty Microcap 250Sector · Compressors Pumps & Diesel Engines peers, median of 12Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Yuken India reported consolidated revenue of Rs 11,253 lakhs for Q2 FY26, down 2.7% YoY. H1 FY26 revenue fell 3.9% to Rs 21,708 lakhs. Consolidated PAT dropped 27% to Rs 512 lakhs in Q2 and 25% to Rs 917 lakhs for H1, pressured by higher depreciation and finance costs. Standalone PAT rose 35.7% to Rs 414 lakhs in Q2. Promoter Yuken Kogyo infused about Rs 59.9 crore via preferential share allotment in July 2025.

Likely market impact

Lower earnings show margin pressure from higher costs. Promoter fund infusion is supportive, but weak revenue trend remains a watch point.